Overview
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
Status:
Completed
Completed
Trial end date:
2011-04-01
2011-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and severe renal insufficiency (Glomerular filtration rate (GFR) < 30 mL/min) for a period of 52 weeks.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
NovartisTreatments:
Sitagliptin Phosphate
Vildagliptin
Criteria
Inclusion Criteria:- Complete the core study and consent for extension
Exclusion Criteria:
- Patient unable to comply with core study requirements